Ascletis Pharma Inc.
ASCLF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $6,429,364 | $1,723,491 | $1,035,754 | $1,266,564 |
| - Cash | $1,580,340 | $865,730 | $342,994 | $330,117 |
| + Debt | $4,267 | $7,633 | $8,853 | $8,416 |
| Enterprise Value | $4,853,291 | $865,394 | $701,613 | $944,863 |
| Revenue | $1,081 | $1,283 | $0 | $10,090 |
| % Growth | -15.7% | – | -100% | – |
| Gross Profit | $121 | $735 | $0 | -$12,630 |
| % Margin | 11.2% | 57.3% | – | -125.2% |
| EBITDA | -$183,676 | -$224,538 | -$165,912 | -$221,651 |
| % Margin | -16,991.3% | -17,501% | – | -2,196.7% |
| Net Income | -$87,951 | -$170,618 | -$130,318 | -$128,156 |
| % Margin | -8,136.1% | -13,298.4% | – | -1,270.1% |
| EPS Diluted | -0.091 | -0.173 | -0.128 | -0.121 |
| % Growth | 47.2% | -34.9% | -6.1% | – |
| Operating Cash Flow | -$172,990 | -$138,164 | -$203,415 | -$76,203 |
| Capital Expenditures | $0 | -$2,095 | $0 | -$4,364 |
| Free Cash Flow | -$172,990 | -$140,259 | -$203,415 | -$80,567 |